Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Projected utility of PARPi in TNBC. Currently, PARPi are used only among germline, BRCA1/2-mutant metastatic TNBC patients, which constitute about 15% of TNBC patients. With the use of strong predictive biomarkers in early TNBC, it is plausible that PARPi sensitivity will be observed in about 60% of TNBC patients (middle panel). In combination with either chemotherapy, immunotherapy, or targeted therapeutics, PARPi sensitivity can potentially increase to 80% of TNBC patients (right panel).